The Institute of Federal Health Care

1
Combining Efforts to Advance The Use and Ease of
E-Prescribing
The Institute of Federal Health Care Interactive
Roundtable October 24, 2008
2
Health Plan Investment in IT

• 40 Member
• Aetna Navigator
• Healthwise Knowledgebase
• Aetna InteliHealth
• Mail-order drug link
• Online medication formulary guide
• Life Insurance calculator
• Aetna HealthFundTM

• 14.8 All
• www.aetna.com
• Clinical Policy Bulletins
• Aetna InteliHealthSM
• DocFind

• 20.3 Plan Sponsor
• EZConnect/SecureTransportTM
• e.Plan Sponsor Monitor
• Online claims detail reports
• EZLink
• EZenroll?
• i.Choose Life Benefits
• FSA Calculator

• 12.7 Physician/Hospital
• ProxyMed/WebMD
• PDA -- electronic prescribing
• e.Health for Physicians
• E-Pay
• Remote disease monitoring
• Online drug/disease interactions
• CAQH

• 12.3 Producer
• Aetna Quoting Center

3
Are Health Plans Willing to Pay?

• Health Plans and PBMs are paying for the
  eligibility transaction costs
• Health Plans pay for direct IT connections
• Focused programs to support Provider start-up
  costs

4
Pocketscript NJ Program MD Adoption of e-Rx
technologyAetna Data Sept 2005 April 2008
5
Pocketscript NJ Program MD Adoption of e-Rx
technology
6
Value and Return on Investment

• Savings from improved formulary prescribing
• Savings from improved generic prescribing
• Medical cost savings from changed or avoided
  prescription adverse events

7
Pocketscript NJ Change in Formulary Rates (Aetna
claims data)
7.1 difference
8
Pocketscript NJ Change in Generic Rates (Aetna
claims data)
7.7 difference
9
Aetna Safety AlertsMarch 1, 2008 May 31, 2008
10
Decision Support - Expanded Communication to
Providers

• Real-time messages that incorporate other medical
  information and message regarding potential gaps
  in care

11
Aetna Health Connections Disease Management-The
Care Engine
MedQuery PTS
Aetna Health Connections DM
12
Decision Support
Diabetes
Diabetes with Microalbuminuria - Consider Adding
an ACE Inhibitor/ARB Your patient has claims
evidence for diabetes, lab data indicating
microalbuminuria, and no claims evidence for an
ACE inhibitor or an angiotensin receptor blocker
(ARB). The American Diabetes Association
recommends that the medical regimen of diabetic
Am J Kidney Dis - K/DOQ1 (Kidney Disease
Out-comes Quality Initiative) Clinical Practice
Guidelines Diabetes Care - American Diabetes
Assoc. Position Statement Standards of Medical
Care in Diabetes.
Provider Text
Used with permission Zix Corp. 2008